News round-up for 19-23 September by DDW Editor Reece Armstrong
An interesting week for clinical research and drug approvals, with rare diseases being a key focus for both the FDA and European Commission.
The last week has seen data emerge on how Omicron infection could protect against influenza, how breast cancer cells evade therapies, and two approvals on rare diseases in the US and EU.
This week’s top stories:
The latest Omicron variants of Covid could be protective against serious influenza infection, a leading testing expert says.
Nefecon has become the first and only approved treatment in the EU for primary immunoglobulin A nephropathy (IgAN), a rare, progressive kidney disease.
A new study has provided the first detailed genetic insights into the pathophysiological mechanisms underpinning Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
SKYSONA has become the first FDA approved therapy to slow the progression of neurologic dysfunction in boys with cerebral adrenoleukodystrophy (CALD).
Scientists have discovered a type of breast cancer cell that is highly efficient in invading and colonising distant organs and slow their growth once there to evade therapies.